Abstract
In this issue of the Journal of Medicinal Chemistry, Janeba et al. found that the in vitro antiviral activity and selectivity index of the aryloxy phosphoramidate (ProTide) prodrug of the acyclic nucleoside phosphonate tenofovir (tenofovir alafenamide) can be dramatically improved by replacing the aryloxy pro-moiety with an appropriate tyrosine derivative. This Viewpoint highlights the possible impact and ramifications that these findings may have in the development of new ProTides.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
